Technology | Intra-Aortic Balloon Pumps (IABP) | May 02, 2017

FDA Clears Teleflex Arrow AC3 Optimus Intra-Aortic Balloon Pump (IABP)

Advanced IABP provides optimized therapy for challenging patient conditions, including severe arrhythmias and heart rates as high as 200 bpm

FDA Clears Teleflex Arrow AC3 Optimus Intra-Aortic Balloon Pump (IABP)

May 2, 2017 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Teleflex Inc. AC3 Optimus Intra-Aortic Balloon Pump (IABP). The device helps augment a weakened heart’s ability to pump blood. This includes a broad range of patients, including those not previously considered candidates for IABP therapy. Clinicians may use the pump on patients with the most severe arrhythmias or with heart rates as high as 200 beats per minute.[1,2]

The AC3 Optimus has a third-generation AutoPilot Mode, which uses proprietary algorithms to address key clinical challenges and to simplify the delivery of IABP therapy.[3] In AutoPilot Mode, the AC3 Optimus automatically adjusts timing and triggering parameters, freeing clinicians to focus on the patient rather than the pump. In addition, the AC3 Optimus includes several exclusive algorithms, such as WAVE Inflation timing, deflation timing management, and best signal analysis, which optimize key functions of the IABP to deliver therapy to the most challenging patients.

“The AC3 Optimus global launch marks a major milestone for Teleflex. This highly anticipated launch will enable the company to become a more significant player with a product that can enhance patient outcomes and make it easier for clinicians to deliver IABP therapy,” said Liam Kelly, president and chief operating officer at Teleflex.

The AC3 Optimus will be launched at two key scientific meetings in May. In North America, it will be on display at the American Association for Thoracic Surgery and American Society of ExtraCorporeal Technology (AATS/AmSECT) annual meeting April 29 - May 3 in Boston. Additionally, it will be on display at the EuroPCR 2017 Conference May 16-19 in Paris, France. 

The device has received its CE mark and has launched in India and parts of Europe.

 

IABP Operation

In IABP therapy, a physician inserts an intra-aortic balloon catheter into an artery, and using X-ray or imaging, advances the catheter into the aorta. The console, connected to the catheter, controls the inflation and deflation of the balloon.

The AC3 Series IABP system provides counter-pulsation therapy to adult patients with impaired left ventricular (LV) Function. It provides hemodynamic support of blood pressure and reduced cardiac work through volume displacement principles. The IABP is attached to an IAB (intra-aortic balloon) catheter which is inserted into the femoral artery and positioned in the descending thoracic aorta.

The IABP delivers helium (HE) into the IAB during diastole to displace blood above and below the IAB, increasing blood pressure and perfusion to organs close to the IAB catheter. The IABP deflates or removes HE from the IAB just prior to or in the early phase of systole, reducing the pressure in the aorta and therefore the pressure the LV must generate to open the aortic valve and eject its contents into the circulatory system. This results in a decrease in work and oxygen demand.

For more information: teleflex.com

Look at a comparison chart of IABPs on the U.S. market. A log in is required, but only takes a minute and is free. 

References:

1. Schreuder J, Castiglioni A, Donelli A, et al. Automatic intraaortic balloon pump timing using an intra beat dicrotic notch prediction algorithm. Ann Thorac Surg. 2005;79(3):1017-1022. Study sponsored by Teleflex. http://www.annalsthoracicsurgery.org/article/S0003-4975(04)01641-8/abstract​

2. Donelli A, Jansen JRC, Hoeksel B, et al. Performance of a real-time dicrotic notch detection and prediction algorithm in arrhythmic human aortic pressure signals. J Clin Monit. 2002;17(3-4):181-185. Study sponsored by Teleflex. https://link.springer.com/article/10.1023/A:1020737232676

3. Torracca, L. Overcoming electro-surgical inference in IABP therapy with the combined use of AutoPilot and FiberOptix IAB sensor signal. 2007. (case report, data on file). Study sponsored by Teleflex.

Related Content

Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.